Loading...

MBRX MOLECULIN BIOTECH INC Expansion Plans 8-K Filing

MLCL

MBRX

MOLECULIN BIOTECH INC

(MBRX)

2026 8-K

Trial Enrollment Update

Corporate Presentation Update

Financial Results Update

Warrant Inducement Agreement

Corporate Presentation

MIRACLE Study Update

Patent Allowance Notification

Stockholder Meeting Results

Corporate Presentation Rele...

Cardiotoxicity Report

Listing Compliance Update

Warrant Amendments

Positive Clinical Results

Compliance Regained

Warrant Exercise Agreement

Enrollment Update

Research Agreement Signed

Stock Split Announcement

Delisting Alert

Enrollment Update

Research Agreement

Investor Presentation

New Cancer Study

Stockholder Meeting Results

Patent Announcement

Clinical Trial Update

Corporate Presentation Rele...

Phase 2B/3 Study

Warrant Exercise Agreement

Stock Increase Approval

Corporate Presentation Update

Annual Meeting Results

Financial Results

Clinical Trials

Investor Meetings

Product Expansion

Equity Offerings

Product Expansion

Notification of Delisting

Equity Offerings

Clinical Trials

Virtual KOL Event

New Product Launches

Compliance Notice

Financial Statements

Clinical Trials

Management Changes

Financial Statements

Asset Acquisitions

Clinical Trials

Investor Presentation

Conference Presentation

Meeting Adjournment

Trial Announcement

Investor Presentation

Financial Results

Patent Announcement

Warrant Agreement

FDA Guidance Received

Regulatory Approval

Warrant Adjustment

Investor Call Update

Investor Update

Business Outlook

Investor Presentation

Investor Presentation

Research Publication

Research Findings

Corporate Presentation

Investor Presentation

Clinical Trial Update

Corporate Presentation

Financial Results

Earnings Announcement

Annual Meeting Results

KOL Event Transcript

KOL Event Announcement

Investor Presentation

Positive Efficacy Data

Investor Conference

Investor Presentation

Clinical Trial Update

Public Offering

Securities Offering

Financial Results

Webcast Presentation

Investor Presentation

FDA Announcement

FDA Meeting Announcement

Clinical Trial Update

Phase 2 Study Commencement

Filing Correction

Earnings Reports

Patent Notification

Corporate Presentation

Announcement of Positive In...

AML Clinical Day

Investor Presentation

Compliance with Bid Price Rule

Patent Notification

Financial Results Announcement

Reverse Stock Split

Investor Presentation

Meeting Results

Management Changes

Securities Purchase Agreements

Investor Presentation

Earnings Reports

Earnings Reports

Clinical Trial Results

Delisting Extension

Special Meeting of Stockhol...

Clinical Trial Completion

Bylaws Amendment

Investor Presentation

Financial Results Announcement

Investigation of Short Selling

Earnings Reports

Conference Presentation

Annual Meeting of Stockholders

Earnings Reports

Clinical Trial Success

Investor Presentation

Earnings Reports

Earnings Reports

Confirmation of No Deposits...

Clinical Trial Results

Termination of Sales Agreement

External Links:

On February 18, 2026, Moleculin Biotech, Inc. announced that 35 patients have been treated in their Phase 2B/3 MIRACLE study for relapsed acute myeloid leukemia, with 11 more in screening, aiming to treat 45 patients by Q1 2026 for data unblinding.

AI Assistant

MOLECULIN BIOTECH INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.